Sign in

1548 on Hong Kong Stock Exchange

GenScript Biotech

Logo: GenScript Biotech, Public domain, via Wikimedia Commons3

Biotechnology group

GenScript Biotech, fully known as GenScript Biotech Corporation, usually referred to as simply GenScript, is a Chinese biotech company. It was co-founded in 2002 in New Jersey by Fangliang Zhang, Ye Wang, and Luquan Wang. Headquartered in Nanjing, the company provides equipment and services for the life sciences.2 Its shares trade on Hong Kong Stock Exchange under the symbol 1548.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

See how the biggest companies compare on our leaderboards

GenScript Biotech, fully known as GenScript Biotech Corporation, usually referred to as simply GenScript, is a Chinese biotech company. It was co-founded in 2002 in New Jersey by Fangliang Zhang, Ye Wang, and Luquan Wang. Headquartered in Nanjing, the company provides equipment and services for the life sciences. It was listed on the Hong Kong Stock Exchange in 2015. The current rotating CEO of the firm is Sherry Shao, who previously served as the chief operating officer and Chinese Communist Party Committee Secretary for the company. The company's subsidiaries include GenScript Life Science Group, ProBio Technology, and Bestzyme.2

The story

GenScript Biotech Corporation was founded in 2002 in New Jersey by Fangliang "Frank" Zhang, Ye "Sally" Wang, and Luquan "Larry" Wang. In 2004, it set up a research and production base in Nanjing, China, where it is now headquartered. It operates in the United States, China, and Singapore.

In 2013, it established its subsidiary Bestzyme. In the following year, another subsidiary, Legend Biotech, was founded. In 2015, GenScript went public on the Hong Kong Stock Exchange.

In 2017, the Chinese government accepted Nanjing Legend's application for running clinical trials for its blood cancer treatment.

In 2020, its subsidiary Probio was launched and Legend Biotech was listed on the NASDAQ. In the same year, Genscript collaborated with Duke-NUS Medical School to develop and manufacture a serology test called cPass for the detection of COVID-19. On November 6, the cPass test received emergency use authorization from the US FDA.

In 2022, Carvykti, a CAR-T cell therapy developed by Janssen Biotech and Legend Biotech, was approved by the US FDA for the treatment of multiple myeloma in adult patients.

From Wikipedia’s article on GenScript Biotech, shared under CC BY-SA 4.0.4

Products and brands

  • biopharmaceutical

Listed on Wikidata.1

Timeline

  1. Dec 30, 2015Went public Listed on Hong Kong Stock Exchange1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4